Staphylococcus Aureus Surgical Site Infection Multinational Epidemiology in Europe

Conditions

Epidemiology, Staphylococcus Aureus, Wound Infection, Surgical

Brief summary

This is a retrospective multinational, multicenter cohort study with a nested case-control. The study includes all surgical procedures performed at a participating site to prevent bias. Data will be assessed in two populations. Cohort population: Export of electronic file data on demographics, surgical procedure ICPM code, duration of procedure, American Society of Anesthesiologists (ASA) score, body mass index, comorbidity ICD codes, and wound class of all patients undergoing surgery. Nested case-control population: For patients establishing S. aureus SSI and 1:1 matched controls from the same center further data will be captured: Length of hospitalization, length of ICU stay and reason as well as attribution to SSI, survival at 30 and at 90 days, antibiotic treatments including duration, functional status at admission and at final discharge; necessity for surgical revision, and death attributed to SSI. If readmission is necessary, reason and attribution to SSI, length of hospitalization and length of ICU stay as well as all antibiotic treatments and their duration will be recorded. The cases causative pathogens including resistance patterns and type of SSI according to CDC criteria will be captured. Matching criteria comprise the following: * Type of procedure * Age * ASA score * BMI * Duration of procedure (as percentile for this procedure) * Diabetes * Sex

Jule Rutz, Jan‐Hendrik Naendrup, C. Bruns, Annika Y. Claßen, Jon Salmanton‐García et al. (28 authors)

JAC-Antimicrobial Resistance2024-03-051 citations

10.1093/jacamr/dlae046

Staphylococcus aureus surgical site infection rates in 5 European countries.

Mellinghoff SC, Bruns C, Albertsmeier M, Ankert J, Bernard L, Budin S, Bataille C, Classen AY, Cornely FB, Couvé-Deacon E, Fernandez Ferrer M, Fortún J, Galar A, Grill E, Guimard T, Hampl JA, Wingen-Heimann S, Horcajada JP, Köhler F, Koll C, Mollar J, Muñoz P, Muñoz P, Pletz MW, Rutz J, Salmanton-García J, Seifert H, Serracino-Inglott F, Soriano A, Stemler J, Vehreschild JJ, Vilz TO, Naendrup JH, Cornely OA, Liss BJ.

2023-09-196 citations

10.1186/s13756-023-01309-w

Harmonized procedure coding system for surgical procedures and analysis of surgical site infections (SSI) of five European countries.

Mellinghoff SC, Bruns C, Al-Monajjed R, Cornely FB, Grosheva M, Hampl JA, Jakob C, Koehler FC, Lechmann M, Maged B, Otto-Lambertz C, Rongisch R, Rutz J, Salmanton-Garcia J, Schlachtenberger G, Stemler J, Vehreschild J, Wülfing S, Cornely OA, Liss BJ.

2022-08-124 citations

10.1186/s12874-022-01702-w

1236. Staphylococcus aureus Surgical Site Infection: Epidemiology in Europe (SALT)

Sibylle C. Mellinghoff, C. Bruns, Markus Albertrsmeier, Matteo Bassetti, Juan Pablo Horcajada et al. (8 authors)

Open Forum Infectious Diseases2019-10-01

10.1093/ofid/ofz360.1099

Epidemiology of Surgical Site Infections With Staphylococcus aureus in Europe: Protocol for a Retrospective, Multicenter Study

Sibylle C. Mellinghoff, Jörg Janne Vehreschild, Blasius Liss, Oliver A. Cornely

JMIR Research Protocols2018-03-1222 citations

10.2196/resprot.8177

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Age ≥18 years at the time of surgery

Exclusion criteria

* Cases with missing data defined as missing completely at random (MCAR) * Infection at the time of surgery

Design outcomes

Primary

Measure	Time frame	Description
To determine overall incidence of Staphylococcus aureus surgical site infections in Europe	30 days from surgical procedure	Surgical site infections will be determined within the cohort of all patients that underwent surgery within 1 year at all participating sites.
To determine procedure specific incidence of Staphylococcus aureus surgical site infections in Europe	30 days from surgical procedure	Surgical site infections will be determined within the cohort of all patients that underwent surgery within 1 year at all participating sites. A subgroup Analysis will reveal procedure specific incidence.

Secondary

Measure	Time frame	Description
To determine the procedure specific outcomes of Staphylococcus aureus surgical site infections in Europe	30 days from surgical procedure	The Outcome will be assessed within the case-control part and achieved by comparison of procedure specific Outcome of cases and controls
To determine the overall outcomes of Staphylococcus aureus surgical site infections in Europe	30 days from surgical procedure	The Outcome will be assessed within the case-control part and achieved by comparison of Overall Outcome of cases and controls
To determine the overall economic burden of Staphylococcus aureus surgical site infections in Europe	30 days from surgical procedure	The economic burden will be assessed within the case-control part and achieved by comparison of Overall economic burden (i.e. ICU Treatment, hemodialysis and mechanical Ventilation) of cases and controls
To determine the procedure specific economic burden of Staphylococcus aureus surgical site infections in Europe	30 days from surgical procedure	The economic burden will be assessed within the case-control part and achieved by comparison of procedure specific economic burden (i.e. ICU Treatment, hemodialysis and mechanical Ventilation) of cases and controls

Other

Measure	Time frame	Description
To estimate the number of patients at risk for Staphylococcus aureus surgical site infection	30 days from surgical procedure	This will be extrapolated from epidemiologcal data assessed within the cohort
To characterize the composition of the surgical patient population in Europe	30 days from surgical procedure	The composition of the surgical patient population in Europe will be performed by subgroup Analysis of the cohort
To estimate the economic burden, including direct treatment and indirect costs, imposed by Staphylococcus aureus surgical site infections in Europe	30 days from surgical procedure	Direct and indirect Treatment costs will be assessed within the case-control part. Cases and controls will be compared regarding costs.

Countries

France, Germany, Italy, Spain, United Kingdom

Outcome results